Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review

Figure 1  Staging system for diabetes mellitus type 1.

Figure 2 Preferred reporting items for systematic reviews and meta-analyses diagram for inclusion of studies discussing the adverse effects of teplizumab. ¹No automation tools used in record search.

Figure 3 Risk of bias assessment using Cochrane's risk of bias tool. Green plus: Low risk; Red minus: High risk; Empty space: Unclear risk.

Figure 4 Teplizumab vs placebo. A: Pooled odds ratio (OR) of total adverse effects in teplizumab vs placebo; B: Pooled OR of gastrointestinal adverse effects in teplizumab vs placebo; C: OR of dermatological adverse effects in teplizumab vs placebo; D: OR of lymphopenia in teplizumab vs placebo.